Telaprevir for the treatment of chronic hepatitis C infection

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 12, 2011, Pages 1105-1114

  Muir, Andrew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antiviral therapy; hepatitis C; protease inhibitors

Indexed keywords

BOCEPREVIR; CYCLOSPORIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; ANTIBIOTIC RESISTANCE; ARTICLE; BONE MARROW SUPPRESSION; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INSOMNIA; LIVER CIRRHOSIS; MOLECULAR PATHOLOGY; NAUSEA; NONHUMAN; PRURITUS; RASH; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THYROID DISEASE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MUTATION; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 82455174551     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.133     Document Type: Article

References (38)

1. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J. Viral. Hepat. 6, 35-47 (1999).
2. Di Bisceglie AM, Lyra AC, Schwartz M et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am. J. Gastroenterol. 98, 2060-2063 (2003).
3. Wise M, Bialek S, Finelli L et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 47(4), 1128-1135 (2008).
4. Jou JH, Muir AJ. In the clinic: hepatitis C. Ann. Intern. Med. 148, ITC6-1-ITC6- 16 (2008).
5. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J. Virol. 83(15), 7366-7374 (2009).
6. Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 130, 225-230 (2006).
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
8. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-a 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
9. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon α-2b or a-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361(6), 580-593 (2009).
10. Armstrong A, Wasley EP, Simard GM, McQuillan WL, Kuhnert, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144, 705-714 (2006).
11. Encke J, Kraus T, Mehrabi A, Stremmel W, Sauer P. Treatment of hepatitis C virus reinfection after liver transplantation. Transplantation 80(Suppl. 1), S125-S127 (2005).
12. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
13. Thompson A, Muir AJ, Sulkowski M et al. IL28b polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 139(1), 120-129 (2010).
14. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin. Gastroenterol. Hepatol. 9(6), 509-516 (2011).
15. Poordad F, McCone J, Bacon B et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
16. Bacon B, Gordon S, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
17. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405-2416 (2011).
18. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364(25), 2417-2428 (2011).
19. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol. Ther. 32, 14-28 (2010).
20. Incivek®, package insert. Vertex Pharmaceuticals Inc., Cambridge, MA, USA (2011).
21. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132(5), 1767-1777 (2007).
22. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-a-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46(3), 631-639 (2007).
23. Sullivan JC, De Meyer S, Bartels DJ et al. Evolution of treatment-emergent resistant variants in the telaprevir Phase III clinical trials. J. Hepatol. 54(Suppl. 1), S4 (2011).
24. Garg V, van Heeswijk R, Eun Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54(1), 20-27 (2011).
25. Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase 1b, placebo-controlled, randomized study. Gastroenterology 131(4), 997-1002 (2006).
26. Lawitz E, Rodriguez-Torres M, Muir AJ et al. Antiviral effects and safety of telaprevir, peginterferon a-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol. 49(2), 163-169 (2008).
27. McHutchison J, Everson G, Gordon S et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009).
28. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
29. McHutchison J, Manns M, Muir A et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303 (2010).
30. Muir AJ, Poordad FF, Shiffman ML et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology doi:10.1002/ hep.24549 (2011) (Epub ahead of print).
31. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365(11), 1014-1024 (2011).
32. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464(7287), 405-408 (2010).
33. Hitomi Y, Cirulli ET, Fellay J et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 140(4), 1314-1321 (2011).
34. Suzuki F, Suzuki Y, Akuta N et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53(2), 415-421 (2011).
35. Chayama K, Hayes CN, Abe H et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 204(1), 84-93 (2011).
36. Kanwal F, Schnitzler M, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann. Intern. Med. 153, 231-239 (2010).
37. Lok A, Gardiner D, Lawitz E et al. Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN/RBV for 2 weeks results in 100% SVR12 in HCV genotype 1 null responders. J. Hepatol. 54(Suppl. 1), S536 (2011).
38. Jacobson I, Catlett I, Marcellin P et al. Telaprevir substantially improved SVR ratesacross all IL28B genotypes in the ADVANCE trial. J. Hepatol. 54(Suppl. 1), S542 (2011).